(NASDAQ: DNLI) Denali Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Denali Therapeutics's revenue in 2025 is $0.On average, 7 Wall Street analysts forecast DNLI's revenue for 2025 to be $5,265,830,010, with the lowest DNLI revenue forecast at $322,513,384, and the highest DNLI revenue forecast at $18,159,537,375. On average, 12 Wall Street analysts forecast DNLI's revenue for 2026 to be $17,030,595,255, with the lowest DNLI revenue forecast at $1,388,841,418, and the highest DNLI revenue forecast at $40,180,518,777.
In 2027, DNLI is forecast to generate $34,550,045,257 in revenue, with the lowest revenue forecast at $15,579,430,305 and the highest revenue forecast at $66,429,040,481.